摘要
目的观察β受体阻滞剂美托洛尔对慢性心力衰竭(CHF)远期预后的影响.方法选择CHF患者65例,随机分为对照组(20例)和治疗组(45例).对照组采用综合疗法.治疗组在上述基础上加用美托洛尔(6.25～12.5 mg/d).在治疗前和观察期满2年时分别对心功能NYHA Ⅱ～Ⅲ患者作踏车负荷试验,记录患者所能耐受的最大运动功率和运动持续时间.结果 2年期间,对照组和治疗组因心力衰竭加重再住院率分别为82.76%和25.58%(P<0.005),病死率分别为31.03%和9.30%(P<0.025);与治疗前相比,治疗组心功能(NYHA分级)、最大运动功率和运动持续时间均明显改善(P<0.001),而对照组各项指标无明显改善.结论美托洛尔可显著改善CHF患者的远期预后.
Objective To investigate the long-term effect of motoprolol on the patients with chronic heart failure（CHF）. Methods Sixty-five CHF patients were divided into the traetment group（45 eases） and the control group（20 cases） randomly. The general therapy was given to the control group. Besides this therapy, motoprolol（6. 25～ 12.5mg） was added to the treatment group. The pedal stress test was performed in the CHF patients with NYHA class Ⅱ - Ⅲ prior to and at the end of 2-year treatment. The maximum motion quantity（Mqmax） and the motion continuance time（MCT） were recorded. Results The rehospiralization rate was 82.76% in the control group and 25.58% in the treatment group（P〈 0.005）. The mortality rare was 31.03 % in the control group and 9.30% in the treatment group（ P 〈 0. 025 ） within 2 years. After 2 years, the heart function （NYHA） , Mqmax and MCT improved obviously in the treatment group（ P 〈 0. 001, respectively）, but did not change significantly in the control group. Conclusion The long-term prognosis can be improved by perindopril in the CHF patients.
出处
《中国基层医药》
CAS
2005年第8期1018-1019,共2页
Chinese Journal of Primary Medicine and Pharmacy
